Skip to main content
Top
Published in: Reactions Weekly 1/2023

01-09-2023 | Prostate Cancer | Case report

Lutetium-(177Lu)-vipivotide-tetraxetan

Grade 2 nephrotoxicity: case report

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Mader N, et al. Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 50 : 1811-1821, No. 6, May 2023. Available from: URL: https://www.springer.com/journal/259 Mader N, et al. Extended therapy with [177Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 50 : 1811-1821, No. 6, May 2023. Available from: URL: https://​www.​springer.​com/​journal/​259
Metadata
Title
Lutetium-(177Lu)-vipivotide-tetraxetan
Grade 2 nephrotoxicity: case report
Publication date
01-09-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-45894-8

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Tozinameran

Case report

Multiple drugs